When Boehringer Ingelheim began closing its Ben Venue site, it justified the decision by describing a grim future for the plant, with operating losses of $700 million forecast over the next 5 years. Now it hopes someone can look past the losses and troubled quality control record to see a business worth buying.
Boehringer Ingelheim is in the midst of closing down its troubled Ben Venue generic sterile injectables facility in Ohio after deciding it was not worth pouring more money into its rehabilitation. But given that there is growth in generic and contract injectable manufacturing, the German company hopes someone might want to take it off its hands.
Boehringer Ingelheim has chosen an antibody therapeutic candidate discovered by Rockville, MD-based MacroGenics for preclinical development.
In a way, the coming year isn't a big one for patent expirations. The total amount of sales jeopardized by patent expirations is $34 billion. That's more than the $28 billion this year, but...
The FDA is expected to approve it, but some analysts wonder how it will fare if a generic of GlaxoSmithKline's Advair makes it to the market.
Boehringer Ingelheim has won over European regulators with its latest COPD therapy, following a favorable FDA panel vote that set the stage for U.S. approval and entrance into a huge but crowded market.
Germany-based Evotec AG has advanced an oncology molecule into preclinical development, raking in a €4 million ($5.4 million) milestone payment from partner Boehringer Ingelheim under a research pact.
After investing more than $350 million in upgrades, Boehringer Ingelheim has decided it is not worth continuing to pour money into its aging Ben Venue Laboratories plant in Bedford, OH, and will shut it down instead, canning the 1,100 people who work there.
The saga of the shortage of ovarian cancer drug Doxil has hit a new turning point, and not for the better. Johnson & Johnson has indicated it will have no supplies of the popular drug until at least the end of next year because its sole supplier is permanently closing the plant that makes it and it will be unable to get new suppliers approved for another 12 months or more.
After years of regulatory woes and drug shortages, Boehringer Ingelheim is calling it quits for Ben Venue, planning to shut down its contract manufacturing arm by year's end and lay off about 1,100 workers.